MannKind Provides Update on Senior Management
May 30 2017 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
announced today that its Board of Directors appointed Michael
Castagna, Pharm.D., as Chief Executive Officer effective May 25,
2017. Dr. Castagna replaced Matthew Pfeffer, who served as both CEO
and Chief Financial Officer since January 2016 and as CFO from 2008
to 2016. To facilitate an orderly transition, Mr. Pfeffer will
continue with the company in an advisory capacity until the end of
July 2017.
In addition, on May 25, 2017, Dr. Castagna was appointed to the
board of directors of MannKind.
Kent Kresa, Chairman of the Board, said, "The Board is extremely
grateful to Matt for his committed service to the company over the
past nine years. Matt successfully set the foundation for the
company during its transition into a commercial entity and
effectively prepared Michael to be his successor.” Mr. Kresa
continued, “Michael demonstrated deep commercial expertise in his
prior role as MannKind’s Chief Commercial Officer as he built the
capabilities from the bottom-up necessary to position Afrezza and
the company for future growth. Under Michael’s leadership, new
prescriptions of Afrezza have shown a steady increase since the
MannKind launch and future prospects for this innovative product
are strong. The Board is excited to move forward under Michael’s
leadership.”
Dr. Castagna said, “I am honored to lead MannKind into its next
phase of growth. Our inhaled insulin, Afrezza, is a truly
differentiated brand that will help millions of people suffering
from diabetes. Our relentless focus on empowering people to conquer
the daily struggle of managing their diabetes will set MannKind
apart.”
Rose Alinaya, currently the company’s Senior Vice President and
Principal Accounting Officer, will take over the role of Acting
Chief Financial Officer until a permanent CFO is named.
Dr. Castagna said, “I am happy to have Rose in this position as
I will benefit greatly from her 14 years of experience with
MannKind. She will be a key asset for me as I take on my new
role.”
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the
discovery, development and commercialization of therapeutic
products for patients with diseases such as diabetes. MannKind
maintains a website at http://www.mannkindcorp.com to
which MannKind regularly posts copies of its press releases as well
as additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its
reports with the Securities and Exchange Commission or posts
certain other information to the website.
Company Contact:
Rose Alinaya
Acting Chief Financial Officer
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024